louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00394017: The Use of Reminders in Implementing an E-learning Program in General Practice
Official title: Implementation of an E-learning Program in Diagnostic Evaluation of Dementia by Reminders: A RCT Among General Practitioners in Copenhagen
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Dementia
Keywords: Heading Health Plan Implementation
Computer-Assisted Instruction
General Practice
Dementia
education
Lead sponsor: Research Unit Of General Practice, Copenhagen
Sponsor class: OTHER
Collaborators: name: Ministry of the Interior and Health, Denmark
First posted: 2006-10-31
Enrollment: 339
Sex: ALL
Minimum age (years): 30
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: To evaluate General Practitioners use and reuptake of an e-learning programme in diagnostic evaluation of dementia after an intervention consisting of three mailed reminder letters.

There is no direct patient involvement in this study.

Detailed description: The three mailed reminder letters will be mailed to the General Practitioners (GPs) in January 2007. The Periods where the e-learning programme will identify GPs using the programme are: Period before: November 1. and 6 weeks forward. Period after: Medio marts and 6 weeks forward.

All log files are kept anonymous for the principal study investigator by the Danish Medical Association.

Eligibility criteria: Inclusion Criteria:

* General Practitioners working in Copenhagen Municipality October 1st 2006

Exclusion Criteria:

* General Practitioners stopping to work in study period

Primary outcomes:
measure: The proportion of General Practices using the e-learning programme at least once in periods monitored.
Secondary outcomes:
measure: The number of logins in the periods monitored.
measure: The time og logins in the periods monitored.
measure: The number of logins in working hours in the periods monitored.
Other outcomes:
Locations:
city: Copenhagen
country: Denmark
facility: Research Unit of General Practice
state: Capital Province
Study officials:
affiliation: Research Unit of General Practice
name: Frans B Waldorff, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03750617: Web-Mediated Risk Assessment for Endoscopic Screening of Colorectal Polyps
Official title: Randomized Trial Comparing Gastroscopy Following Web-Mediated Risk Assessment With Routine Endoscopy Screening of Colorectal Polyps
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Colorectal Polyp
Keywords: Colorectal Polyp
Screening
Risk assessment
Lead sponsor: State Key Laboratory of Cancer Biology
Sponsor class: NETWORK
Collaborators: name: Xijing Hospital
name: Tang-Du Hospital
First posted: 2018-11-23
Enrollment: 1000
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: Colorectal polyps are risk factors for cancer. Early detection of polyps is critical for colorectal cancer management. However, the diagnosis rate of patients with colorectal polyps is still low. Therefore, we design this study to access whether pre-endoscopic screening risk assessment of genetic and environmental risk factors could improve diagnosis rate of colorectal polyps.


Eligibility criteria: Inclusion Criteria:

1. Age 18-65.
2. Signed informed consent

Exclusion Criteria:

1. Severe back ground disease including malignancy.
2. State after gastric surgery.
3. COPD, CHF, CRF and any disease with respiratory disturbances.
4. Deviation of the nasal septum, lack of venous access at the dorsum of the hand or any other technical problem prevents gastric acid collection or base excess evaluation.

Primary outcomes:
measure: Diagnostic rate of patients with polyps
timeFrame: 2 year
Secondary outcomes:
measure: Number and characteristics of polyps detected
timeFrame: 2 year
Other outcomes:
Locations:
city: Xi'an
country: China
facility: State Key laboratory of Cancer Biology
state: Shaanxi
Study officials:
References:
Clinical trial NCT05178017: Lifestyle Eating and Performance (LEAP) Program for the Treatment of Irritable Bowel Syndrome (IBS)
Official title: Effectiveness of the Lifestyle Eating and Performance (LEAP) Program for the Treatment of Irritable Bowel Syndrome (IBS)
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: IBS - Irritable Bowel Syndrome
Lead sponsor: Oxford Biomedical Technologies, Inc.
Sponsor class: INDUSTRY
First posted: 2022-01-05
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: A three month follow-up study to evaluate the effectiveness of a tailored anti-inflammatory eating plan guided by a registered dietitian to treat irritable bowel syndrome.

Detailed description: This study will have 60 participants with Irritable bowel syndrome (IBS) for a duration of three months. The procedures will consist of anthropometric measures, blood pressure, questionnaires, and a blood sample. There will be seven visits with one including a virtual meeting with a registered dietitian involved in the Lifestyle Eating and Performance (LEAP) program. With these procedures the investigators will test the effectiveness of the LEAP program for the treatment of irritable bowel syndrome by improving inflammatory markers, symptoms, and quality of life.

Eligibility criteria: Inclusion Criteria:

* Adult patients with an established diagnosis of IBS-D as determined by Rome III or IV Criteria
* Have IBS of at least moderate severity
* Must be on a stable dose regimen for at least 1 month prior to enrollment
* Willing to follow the LEAP program for 3 months
* Able to give informed consent
* Willing to complete the study

Exclusion Criteria:

* Individuals with a history of inflammatory bowel disease, celiac disease, abdominal surgeries, cancer patients under treatment, and kidney failure
* BMI of 40 or higher
* Pregnancy or planned pregnancy or lactation
* Any serious illness that will interfere with the study procedures or results
* Enrollment in active clinical trial/ experimental therapy within the last 30 days
* Currently on another dietary treatment approach

Primary outcomes:
measure: Inflammatory blood markers
timeFrame: 3 months
Secondary outcomes:
measure: Gastrointestinal symptoms severity
timeFrame: 3 months
measure: The quality of life
timeFrame: 3 months
Other outcomes:
Locations:
city: Riviera Beach
country: United States
facility: Oxford Biomedical Technologies, Inc.
state: Florida
Study officials:
affiliation: Oxford Biomedical Technologies, Inc.
name: Gustavo Zarini, Ph.D., RD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01226017: A Possible Effect of Oxytocin During Interaction Between Humans and Animals
Official title: A Possible Effect of Oxytocin During Interaction Between Humans and Animals
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Animal Assisted Therapy
Keywords: Oxytocin
Animal Assisted therapy
Farm animals
Healthy nursing students
Lead sponsor: Norwegian University of Life Sciences
Sponsor class: OTHER
First posted: 2010-10-21
Enrollment: 18
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 30
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: The purpose of this pilot study is to investigate the possible change of Oxytocin level in human blood after positive interaction with farm animals.

Detailed description: The purpose of this pilot study is to investigate the possible change of Oxytocin level in human blood after positive interaction with farm animals and filling in instruments measuring anxiety and stress.

Eligibility criteria: Inclusion Criteria:

* woman
* age 20-30 years old
* physical capable of being in a farm environment and have contact with cows

Exclusion Criteria:

* pregnancy
* breastfeeding
* anxiety for blood sampling
* anxiety for animals
* allergies
* psychiatric diagnoses
* medication

Primary outcomes:
measure: Measuring the possible change in Oxytocin level in human blood during intervention with farm animals.
timeFrame: Start medio October 2010, and end December 2011 (14 months)
Secondary outcomes:
measure: Self evaluation of anxiety and coping strategies.
timeFrame: Start medio October 2010, and end December 2011 (14 months)
Other outcomes:
Locations:
city: Aas
country: Norway
facility: Norwegian University of Life sciences
Study officials:
affiliation: Norwegian University of Life Sciences
name: Bente Berget, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01774617: Comparative Analysis of Different Tests to Evaluate Prognosis of Patients on Liver Transplant Waiting List
Official title: Comparative Analysis of Indocyanine Green Clearance Test, MELD Score, MELD-Na Score, Transient Elastography and Hepatic Venous Pressure Gradient to Evaluate Prognosis of Patients on Liver Transplant Waiting List
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cirrhosis
Liver Failure
Portal Hypertension
Keywords: portal hypertension
elastography
Hepatic venous pressure gradient measurement
Lead sponsor: Universidade Federal do Rio de Janeiro
Sponsor class: OTHER
Collaborators: name: Rio de Janeiro State Research Supporting Foundation (FAPERJ)
First posted: 2013-01-24
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Maximum age (years): 69
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Cirrhotic patients on the liver transplantation waiting list of a single center.

Brief summary: It is a cohort to evaluate the power of different diagnostic tests in predicting the prognosis of patients with severe liver disease.

Patients with decompensated liver cirrhosis on the waiting list for liver transplantation will be evaluated with comparison of different diagnostic tests according to the MELD score (Model for End-Stage Liver Disease), MELD-Na (Model for End-Stage Liver Disease and sodium), indocyanine green clearance test, hepatic venous pressure gradient and transient elastography. All patients will be submitted to all the tests and prospectively followed for 6 months, to establish mortality and complications related to liver disease in order to define the value of each method to predict outcomes.


Eligibility criteria: Inclusion Criteria:

* the study includes patients (80 patients)
* were male and female
* aged between 18 and 69 years with chronic liver disease
* with MELD inclusion greater than or equal to 14 to 30

Exclusion Criteria:

* they have been transplanted
* have a diagnosis of primary malignant liver (HCC) signed by imaging tests performed
* MELD scores greater than 30.

Primary outcomes:
measure: All cause mortality
timeFrame: 6 months
Secondary outcomes:
measure: Chronic liver failure and portal hypertension complications
timeFrame: 6 months
Other outcomes:
Locations:
city: Rio de Janeiro
country: Brazil
facility: Hospital Universitário Clementino Fraga Filho / Federal University of Rio de Janeiro
state: RJ
Study officials:
affiliation: Universidade Federal do Rio de Janeiro
name: Guilherme FM Rezende, MD PhD
role: STUDY_CHAIR
References:
Clinical trial NCT02945917: Positive End-expiratory Pressure and Esophageal Catheter Optimal Calibration Volume in ARDS Patients
Official title: Positive End-expiratory Pressure and Esophageal Catheter Optimal Calibration Volume in ARDS Patients
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: ARDS
Lead sponsor: San Gerardo Hospital
Sponsor class: OTHER
First posted: 2016-10-26
Enrollment: 16
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: ARDS patients undergoing volume control mechanical ventilation

Brief summary: The use of esophageal balloon catheter to estimate pleural pressure has gained renewed popularity in recent years. Indeed, measurement of transpulmonary pressure may allow a more pathophysiological-based approach to ventilator strategy in acute respiratory distress syndrome (ARDS) patients. Nevertheless, it is well known that esophageal balloon catheter derived parameters can be influenced by several patient-related or technical-related factors.

During a PEEP trial, the investigators will observe in-vivo the esophageal pressure and derived measurements obtained using different esophageal balloon calibration volumes.


Eligibility criteria: Inclusion Criteria:

* Diagnosis of ARDS with a PEEP of at least 8 cmH2O
* Fraction of inspired oxygen not higher than 80%
* Intubated and ventilated in Volume Control Ventilation mode set by the attending physician according to clinical criteria
* Need of continuous sedation through intravenous anesthetics and full neuromuscular blockade

Exclusion Criteria:

* Been pregnant or breastfeeding
* Hemodynamic instability
* Presence of tracheobronchial fistula
* Known pneumothorax
* Leak in airway circuitry
* Presence of any kind of inhalator therapy (e.g. Heliox, nitric oxide, anesthetic conserving device)
* Recent history of nasal trauma or lesion of nasal cavity
* Recent history of esophageal, gastrointestinal, ENT, thoracic or cardiac surgery (less than 2 months)
* Known or suspected esophageal varices
* Congenital, acquired or drug-induced hemostatic disorder
* Thrombocytopenia (less than 50000/mm3)
* Recent history of Traumatic Brain Injury or thoraco-abdominal trauma (less than 1 months)
* Rib or sternal fractures

Primary outcomes:
measure: transpulmonary pressure measured estimating pleural pressure through the esophageal balloon
timeFrame: within 10 minutes after esophageal balloon volume changing
Secondary outcomes:
measure: End-expiratory lung volume
timeFrame: within 60 minutes after PEEP changing
Other outcomes:
Locations:
city: Monza
country: Italy
facility: UOC Anestesia e Rianimazione
state: Monza e Brianza
Study officials:
References:
Clinical trial NCT00960817: "Normal Coronary Artery" With Slow Flow Improved by Adenosine Injection, Dipyridamole Treatment and Clinical Follow-up
Official title: "Normal Coronary Artery" With Slow Flow Improved by Adenosine Injection, Dipyridamole Treatment and Clinical Follow-up
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: EARLY_PHASE1
Conditions: Coronary Angiography
Keywords: Normal coronary artery with slow blood flow
Lead sponsor: Hillel Yaffe Medical Center
Sponsor class: OTHER_GOV
First posted: 2009-08-18
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no

Brief summary: The investigators will investigate patients undergoing coronary angiography with normal coronary but slow blood flow that was normalized after adenosine injection into the coronary artery. The investigators believe that they have small vessel coronary disease which is the initial presentation of coronary disease prior to anatomical narrowing. To alleviate this phenomenon the investigators intend to examine the long-term clinical response of these patients to treatment with dipyridamole, a well-known medication with almost no side-effects that increases the level of adenosine in the tissue.


Eligibility criteria: Inclusion Criteria:

* Patients undergoing coronary angiography and who have normal coronary artery with slow blood flow that normalized with adenosine injection into the coronary artery

Exclusion Criteria:

* Significant coronary disease
* Unstable patients
* Patients with known sensitivity to dipyridamole

Primary outcomes:
measure: Alleviation of chest pain
timeFrame: Two years
Secondary outcomes:
Other outcomes:
Locations:
city: Hadera
country: Israel
facility: Hillel Yaffe Medical Center
Study officials:
References:
Clinical trial NCT01344317: The Effect of Stimulating Substances on Brain Activity of Preterm Infants
Official title: The Effect of Stimulating Substances on Brain Activity Measured by Amplitude-integrated EEG and Long-term Neurodevelopmental Outcome of Preterm Infants Born Below 30 Weeks of Gestation
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Apneas of Prematurity
Lead sponsor: Medical University of Vienna
Sponsor class: OTHER
First posted: 2011-04-29
Enrollment: 60
Sex: ALL
Minimum age (years): 23
Maximum age (years): 30
Standard ages: CHILD
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Preterm infants born below a gestational age of 30 weeks

Brief summary: Introduction: Methylxanthines and doxapram have been widely used for the treatment of apneas of prematurity. Both substances have effects on the central nervous system. While there are data available concerning the use of caffeine (the methylxanthine used at our NICU) even proposing a positive effect on neurodevelopmental outcome of very preterm infants, there are data which suggest a negative effect of the central stimulants doxapram on longterm outcome in this group of infants. Nevertheless concerning both medications only few studies have been published and only scarce data are available concerning the effect of these medications on brain activity of very preterm infants until now.

The aim of this study: is the assessment of the effect of stimulating substances on brain activity of preterm infants born below 30 weeks of gestation and their longterm neurodevelopmental follow-up.

Methods: This study is a prospective study including preterm infants born below 30 weeks of gestational age. Brain activity is measured by one-channel amplitude-integrated EEG (aEEG). The first aEEG measurement is performed without caffeine and/or doxapram medication. At least one hour of brain activity is registrated. The second measurement is done at least 24 hours after the start of caffeine and/ or doxapram treatment.

The percentage of different background patterns, the occurrence and duration of sleep-wake-cycling, and the occurrence and duration of seizures is assessed and analysed. Neurodevelopmental outcome is assessed at one and two years of corrected age by assessment of the Bayley Scales of Infant Development II and standardized clinical neurological examination.


Eligibility criteria: Inclusion Criteria:

see above

Exclusion Criteria:

* intraventricular hemorrhage
* posthaemorrhagic hydrocephalus
* cerebral infection
* cerebral malformation

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Vienna
country: Austria
facility: Medical University of Vienna, Department of Pediatrics and Adolescent Medicine, Neonatology
city: Vienna
country: Austria
facility: Medical University of Vienna
Study officials:
affiliation: Medical University of Vienna
name: Manfred Weninger, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01569217: Regional Distribution of Ventilation to Assess Respiratory Muscle Dysfunction
Official title: Construction of a Database to Identify Early Indicators of Respiratory Muscle Dysfunction in Neuromuscular Patients From the Optoelectronic Plethysmography Assessment of the Thoracoabdominal Motion
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Respiratory Failure
Neuromuscular Disorder
Diaphragmatic Paralysis
Keywords: Diaphragm
Abdomen
Breathing pattern
dyspnea
Lead sponsor: Centre d'Investigation Clinique et Technologique 805
Sponsor class: OTHER
First posted: 2012-04-03
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Neuromuscular patients

Brief summary: The aim of this study is to better discriminate respiratory muscle dysfunction by comparing the measurements of thoracoabdominal motion obtained by an optoelectronic recording and the conventional tests of respiratory muscle strength. The final objective is to better select in the future the patients who need more specific assessment of diaphragmatic function like "maximal transdiaphragmatic pressure" measurement and "phrenic nerve stimulation".

Detailed description: All patients which had suspected respiratory muscle dysfunction will have usual exploration of the respiratory muscles according to the clinician prescription. These explorations can include :

* Lung volumes in seating and supine position
* Maximal inspiratory and expiratory pressures
* Maximal sniff pressures

And when diaphragmatic dysfunction is suspected :

* Maximal transdiaphragmatic pressure
* Phrenic nerve conduction

These patients will also beneficiate to the determination of volume variations of the upper rib cage, the lower rib cage and the abdominal compartments by using Opto-electronic plethysmography.

Eligibility criteria: Inclusion Criteria:

* suspicion of respiratory muscle dysfunction
* indication of diaphragm exploration

Exclusion Criteria:

* acute respiratory failure

Primary outcomes:
measure: compartmental distribution of the inspired/expired volumes
timeFrame: 1 hour
Secondary outcomes:
measure: left side and right side contribution to the inspired/expired volumes
timeFrame: 1 hour
Other outcomes:
Locations:
city: Garches
country: France
facility: Raymond Poincaré Hospital
Study officials:
affiliation: Centre d'Investigation Clinique et Technologique 805
name: Frédéric Lofaso, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: